Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
Speak to your health care professional to determine your personal high and low glucose alert levels. Do not change your glucose alert levels without consulting with your health care professional.
The high and low glucose levels in the app are pre-set, but can be customized to your preferences. Based on the preset (default) glucose levels:
“HI” Reading Indicates a sensor glucose reading is greater than 400 mg/dL
“LO” Reading Indicates sensor glucose reading is less than 40 mg/dL
Operational Conditions: 5 - 40 °C (41 - 104 °F)
Storage Conditions: 0 - 35 °C (32 - 95 °F)
Cabin Pressure: 700hPa to 1060hPa
Altitude: 10,000 feet (3,048 meters)
Relative Humidity Range (non-condensing): 15% to 90%
Protection Against Electrical Shock: Type BF applied part
If you do not have access to a blood glucose meter when you receive a calibration prompt, your Eversense E3 CGM system will continue to provide glucose readings for up to 4 additional hours. You should take action during this time to obtain your blood glucose meter. After the 4 hours, you will receive a Calibration Past Due alert and no glucose values will be displayed until the next calibration is entered.
Even with a non-adjunctive CGM system, you should always carry a blood glucose meter with you as you should always be prepared to take a blood glucose test when prompted for a calibration or when any of the following situations occur:
- Your symptoms do not match the glucose value displayed on your app
- No glucose value is displayed (during system initialization, for example)
- Your system prompts you to use your BG meter for making a treatment decision in the app status bar
- You are taking medications of the tetracycline class
It takes approximately 15 minutes to fully charge a smart transmitter when plugged into a wall outlet. It may take longer if charging via a computer USB port or when the battery is empty.
The Eversense® E3 CGM System has not been tested in the following populations: women who are pregnant or nursing, people under the age of 18, critically ill or hospitalized patients, people receiving immunosuppressant therapy, chemotherapy or anti-coagulant therapy, those with another active implantable device, e.g., an implantable defibrillator (passive implants are allowed, e.g., cardiac stents), those with known allergies to or using systemic glucocorticoids (excluding topical, optical or nasal, but including inhaled).
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1